Outcome of patients treated by intravitreal injections during the COVID-19 lockdown: An institutional experience.

Georges SukkariehSophie BonninGeorges AzarJustine LafolieAnne-Sophie AlonsoOzlem ErolJustine PineauHélène VillainJessica GuillaumeEmmanuel AugeAlain MingouRaphael LejoyeuxVivien VasseurMartine Mauget-Faÿsse

Published in: Current eye research (2023)

COVID-19 lockdown did not seem to negatively affect the 1-year outcome of patients with retinal diseases treated by anti-VEGF IVIs who missed their scheduled injections. The BCVA and rate of complications at 1 year did not differ whether patients missed or not their scheduled injections. Maintaining IVIs during lockdown periods and educating patients about the risks of missing injections are pivotal in improving prognosis of retinal diseases.

Keyphrases

end stage renal disease
newly diagnosed
coronavirus disease
ejection fraction
sars cov
chronic kidney disease
ultrasound guided
optical coherence tomography
prognostic factors
platelet rich plasma
endothelial cells
risk factors
respiratory syndrome coronavirus
patient reported